Bepirovirsen 治疗慢性乙型肝炎的 2 期随机对照试验:安全性、耐受性与抗病毒活性
这项 2 期双盲、随机、安慰剂对照试验在初治和核苷(酸)类似物(NA)抑制的慢性乙型肝炎患者中评估反义寡核苷酸 bepirovirsen 的安全性与抗病毒活性。主要目的是安全性,次要目的包括第 29 天血清 HBsAg 较基线变化。初治患者接受 300 mg bepirovirsen 的 HBsAg 下降显著优于安慰剂。
要点
- Bepirovirsen 总体安全性良好,不良事件多为轻中度,常见注射部位反应。
- 初治患者 300 mg 组第 29 天 HBsAg 下降显著优于安慰剂(P = 0.001)。
- 150 mg 组及稳定 NA 治疗者 HBsAg 下降未显著优于安慰剂。
核心结论
- Bepirovirsen 在慢性乙型肝炎患者中安全性良好,并在初治患者 300 mg 组观察到显著 HBsAg 下降。
- 这些初步观察值得在更大慢性乙型肝炎人群中进一步研究其安全性和活性。
研究设计与样本
- 2 期双盲、随机、安慰剂对照试验(NCT02981602),评估 bepirovirsen 的安全性与抗病毒活性。
- 纳入慢性 HBV 感染≥6 个月且血清 HBsAg≥50 IU/ml 的患者,来自香港和韩国七个中心。
- 按每个剂量队列 3:1 随机接受 bepirovirsen 或安慰剂皮下注射,第 1–2 周每周两次(第 1、4、8、11 天),第 3–4 周每周一次(第 15、22 天),随后随访 26 周。
- 共 24 例初治患者和 7 例接受稳定 NA 治疗者。
主要发现
- 治疗中出现的不良事件多为轻中度,最常见注射部位反应。
- 初治患者中,bepirovirsen 组 11 例(61.1%)和安慰剂组 3 例(50.0%)发生至少一次治疗中出现的不良事件。
- 接受 NA 治疗者中,相应人数为 3 例(60.0%)和 1 例(50.0%)。
- 初治患者中 8 例和稳定 NA 治疗者中 3 例在接受 bepirovirsen 的治疗组出现短暂自限性 ALT 升高(≥2×正常上限)。
- 初治患者接受 bepirovirsen 300 mg 的 HBsAg 下降显著优于安慰剂(P = 0.001),150 mg 组(P = 0.245)和稳定 NA 治疗者(P = 0.762)未达显著。
关键数值与推荐
- 初治患者 bepirovirsen 300 mg 组 HBsAg 较基线下降显著优于安慰剂(P = 0.001)。
- 初治患者 bepirovirsen 150 mg 组 HBsAg 下降与安慰剂比较 P = 0.245。
- 接受稳定 NA 治疗者 HBsAg 下降与安慰剂比较 P = 0.762。
- 两个 300 mg 剂量组各有 2 例患者在第 29 天(n = 3)或第 36 天(n = 1)HBsAg 低于定量下限。
临床怎么用
- Bepirovirsen 在慢性乙型肝炎中显示出可接受的安全性,支持进一步开展更大规模研究。
- 初治患者 300 mg 剂量与显著 HBsAg 下降相关,但需更大样本验证。
- 治疗中可出现短暂自限性 ALT 升高,需在临床研究中监测。
局限性
- 研究仅纳入香港和韩国七个中心的患者。
- 随访期有限,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic infection with hepatitis B virus (HBV) leads to an increased risk of death from cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment options (nucleos(t)ide analogs (NAs) and pegylated interferons). Bepirovirsen is an antisense oligonucleotide targeting all HBV messenger RNAs; in cell culture and animal models, bepirovirsen leads to reductions in HBV-derived RNAs, HBV DNA and viral proteins. This phase 2 double-blinded, randomized, placebo-controlled trial is the first evaluation of the safety and activity of an antisense oligonucleotide targeting HBV RNA in both treatment-naïve and virally suppressed individuals with chronic HBV infection. The primary objective was to assess the safety and tolerability of bepirovirsen in individuals with chronic hepatitis B (CHB) (NCT02981602). The secondary objective was to assess antiviral activity, including the change from baseline to day 29 in serum hepatitis B surface antigen (HBsAg) concentration. Participants with CHB infection ≥6 months and serum HBsAg ≥50 IU ml-1 were enrolled from seven centers across Hong Kong and the Republic of Korea and randomized (3:1 within each dose cohort) to receive bepirovirsen or placebo via subcutaneous injection twice weekly during weeks 1 and 2 (days 1, 4, 8 and 11) and once weekly during weeks 3 and 4 (days 15 and 22). Participants were then followed for 26 weeks. Twenty-four participants were treatment-naïve and seven were receiving stable NA therapy. Treatment-emergent adverse events were mostly mild/moderate (most commonly injection site reactions). Eleven (61.1%) and three (50.0%) treatment-naïve participants experienced one or more treatment-emergent adverse event in the bepirovirsen and placebo groups, respectively. In participants receiving NA therapy, the corresponding numbers were three (60.0%) and one (50.0%). Transient, self-resolving alanine aminotransferase flares (≥2× upper limit of normal) were observed in eight treatment-naïve participants and three participants on stable NA regimens in the bepirovirsen treatment arms. HBsAg reductions were observed and were significant versus placebo for treatment-naïve participants receiving bepirovirsen 300 mg (P = 0.001), but not for the bepirovirsen 150 mg group (P = 0.245) or participants receiving stable NA therapy (P = 0.762). Two participants in each of the 300 mg dose groups achieved HBsAg levels below the lower limit of quantitation by day 29 (n = 3) or day 36 (n = 1). Bepirovirsen had a favorable safety profile. These preliminary observations warrant further investigation of the safety and activity of bepirovirsen in a larger CHB patient population.
引用
- Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021. PMID: 34642494. doi:10.1038/s41591-021-01513-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。